γ-ray mutagen sensitivity and survival in patients with glioma

Clinical Cancer Research

Volumn 4, Issue 12, 1998, Pages 3031-3035

  Sigurdson, Alice J ^a   Bondy, Melissa L ^a,b   Hess, Kenneth R ^a   Toms, Steven A ^a   Kyritsis, Athanassios P ^b   Gu, Jun ^a   Wang, Li E ^a   Wang, Xinzhi ^a   Adatto, Phyllis ^a   Bruner, Janet L ^a   Yung, W K Alfred ^b   Levin, Victor A ^b   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN BIOPSY; BRAIN SURGERY; CANCER SURVIVAL; CHROMOSOME BREAKAGE; FEMALE; GAMMA IRRADIATION; GLIOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METAPHASE CHROMOSOME; MUTAGEN TESTING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GAMMA RAYS; GLIOMA; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PROGNOSIS; RADIATION TOLERANCE; SURVIVAL RATE;

EID: 17444379728     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Levin, V. A., Leibel, S. A., and Gutin, P. H. Neoplasms of the central nervous system. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Vol. 2., Ed. 5, pp. 2022-2082. Philadelphia: Lippincott-Raven, 1997.
2. Spitz, M. R., Hoque, A., Trizna, Z., Schantz, S. P., Amos, C. I., King, T. M., Bondy, M. L., Hong, S. K., and Hsu, T. C. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J. Natl. Cancer Inst., 86: 1681-1684, 1994.
3. Spitz, M. R., Lippman, S. M., Jiang, H., Lee, J. J., Khuri, F., Hsu, T. C., Trizna, Z., Schantz, S. P., Benner, S., and Hong, W. K. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J. Natl. Cancer Inst., 90: 243-245, 1998.
4. Bondy, M. L., Kyritsis, A. P., Gu, J., deAndrade, M., Cunningham, J., Levin, V. A., Bruner, J. M., and Wei, Q. Mutagen sensitivity and risk of gliomas: a case-control analysis. Cancer Res., 56: 1484-1486, 1996.
5. Ron, E., Modan, B., Boice, J. D., Jr., Alfandary, E., Stovall, M., Chetrit, A., and Katz, L. Tumors of the brain and nervous system after radiotherapy in childhood. N. Engl. J. Med., 319: 1033-1039, 1988.
6. Wei, Q., Spitz, M. R., Gu, J., Cheng, L., Xu, X., Strom, S. S., Kripke, M. L., and Hsu, T. C. DNA repair capacity correlates with mutagen sensitivity in lymphoblastoid cell lines. Cancer Epidemiol. Biomark. Prev., 5: 199-204, 1996.
7. Hsu, T. C., Johnston, D. A., Cherry, L. M., Ramikisson, D., Schantz, S. P., Jessup, J. M., Winn, R. J., Shirley, L., and Furlong, C. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int. J. Cancer, 43: 403-409, 1989.
8. Hsu, T. C., Shillitoe, E. J., Cherry, L. M., Lin, Q., Schantz, S. P., and Furlong, C. Cytogenetic characterization of 20 lymphoblastoid lines derived from human individuals differing in bleomycin sensitivity. In Vitro Cell Dev. Biol., 26: 80-84, 1990.
9. Lee, J. J., Trizna, Z., Hsu, T. C., Spitz, M. R., and Hong, W. K. A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay. Cancer Epidemiol. Biomark. Prev., 5: 191-197, 1996.
10. Therneau, T. M., Grambsch, P. M., and Fleming, T. R. Martingale-based residuals for survival models. Biometrika, 77: 147-160, 1990.
11. Efron, B., and Tibshirani, R. J. An introduction to the bootstrap. New York: Chapman and Hall, 1993.
12. Schiffer, D., Cavalla, P., Chio, A., Richiardi, P., and Giordana, M. T. Proliferate activity and prognosis of low-grade astrocytomas. J. Neurooncol., 34: 31-35, 1997.
13. Korkolopoulou, P., Christodoulou, P., Kouzelis, K., Hadjiyannakis, M., Priftis, A., Stamoulis, G., Seretis, A., and Thomas-Tsagli, E. MDM2 and p53 expression in gliomas: a multivariate survival analysis includ-ing proliferation markers and epidermal growth factor receptor. Br. J. Cancer, 75: 1269-1278, 1997.
14. Pollack, I. F., Hamilton, R. L., Finkelstein, S. D., Campbell, J. W., Martinez, A. J., Sherwin, R. N., Bozik, M. E., and Gollin, S. M. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res., 57: 304-309, 1997.
15. Rainov, N. G., Dobberstein, K. U., Bahn, H., Holzhausen, H. J., Lautenschlager, C., Heidicke, V., and Burkert, W. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J. Neurooncol., 35: 13-28, 1997.
16. Kyritsis, A. P., Bondy, M. L., Hess, K. R., Cunningham, J. E., Zhu, D., Amos, C. I., Yung, W. K. A., Levin, V. A., and Bruner, J. A. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin. Cancer Res., 1: 1617-1622, 1995.
17. Wei, Q., and Spitz, M. R. The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev., 16: 295-307, 1997.
18. Spitz, M. R., Hsu, T. C., Wu, X., Fueger, J. J., Amos, C. I., and Roth, J. A. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol. Biomark. Prev., 4: 99-103, 1995.
19. Wu, X., Hsu, T. C., Annegers, J. F., Amos, C. I., Fueger, J. J., and Spitz, M. R. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases. Cancer Res., 55: 557-561, 1995.